Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15

Prostate Cancer Clinical Trial

Official title:

Proteomic Analysis of the Combined Hormonal Therapy and Radiation Therapy for Localized Prostate Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00955435
• Other study ID #: CTRIAL-IE (ICORG) 06-15
• Secondary ID: CTRIAL-IE (ICORG
• Status: Active, not recruiting
• Start date: February 2006

Study information

• Verified date: February 2021
• Source: Cancer Trials Ireland
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This clinical trial is studying blood and urine samples in patients with newly diagnosed localized prostate cancer treated with hormone therapy and radiation therapy.

Description:

OBJECTIVES:

• Detect changes in serum and urine proteomic profiles that predict outcome in patients with newly diagnosed localized prostate cancer treated with hormonal therapy and radiotherapy.

• Identify prognostic and biochemical markers of early disease progression in patients treated with this regimen.

• Identify unique protein expression and temporal alterations, in these profiles, that facilitate understanding of the factors predicting relapse or toxicity.

• Identify molecular signatures that allow identification of targets for therapeutic intervention.

OUTLINE: This is a multicenter study.

Patients receive induction hormones* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy (per standard treatment). Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.NOTE: * Patients receiving short-term hormonal treatment for 4-8 months are eligible to participate in the trial.

Blood and urine samples are collected at baseline, and periodically during and after induction therapy for proteomic analysis.

After completion of study therapy, patients are followed up periodically for 5 years and yearly thereafter for the duration of the trial.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Age 18 years or over.

2. Histologically confirmed invasive adenocarcinoma of the prostate (by TURP or TRUS).

3. Localised prostate cancer with a Gleason score 7

4. Short term hormonal treatment 4-8 months

5. Performance status of KPS = 60 / WHO 0-2

6. Absence of distant metastases

Exclusion criteria:

1. The patient has previously received treatment for prostate cancer other than TURP/ TRUS

2. The patient has had a bilateral orchidectomy

3. The patient has previously received hormonal treatment for prostate cancer

4. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial. In the opinion of the investigator, any evidence of severe or uncontrolled systematic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease

5. The patient has or had other co-existing malignancies within the past 5 years other than non- melanoma skin cancer

6. Treatment with non-approved or investigational drug within 30 days before day one of the trial

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• Non-interventional
Patients receive induction hormones* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy per standard treatment. Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.

Genetic:
• Protein expression analysis

• Proteomic profiling

Other:
• Laboratory biomarker analysis

Locations

Country	Name	City	State
Ireland	Beacon Hospital	Dublin
Ireland	Saint Luke's Radiation Oncology Network	Dublin

Sponsors (1)

Lead Sponsor	Collaborator
Cancer Trials Ireland

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in serum and urine proteomic profiles		Ongoing until patient progression
Primary	Prognostic and biochemical markers of early disease progression		Ongoing until patient progression
Primary	Protein expression and temporal alterations		Ongoing until patient progression
Primary	Molecular targets		Ongoing until patient progression